MDT-AP-2304
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 7.4
- sex
- M
- new_clusters
- C4
- umap1_2d
- 4.185684775
- umap2_2d
- 3.372139728
- umap1_3d
- 1.351721103
- umap2_3d
- -1.38018787
- umap3_3d
- -1.586084515
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.470
- ALLOGRAFT_REJECTION+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- INTERFERON_GAMMA_RESPONSE+0.450
- E2F_TARGETS+0.440
- G2M_CHECKPOINT+0.400
- INFLAMMATORY_RESPONSE+0.390
- IL6_JAK_STAT3_SIGNALING+0.350
- COAGULATION+0.330
- COMPLEMENT+0.330
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.440
- MYC_TARGETS_V2-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.300
- PEROXISOME-0.270
- MYC_TARGETS_V1-0.220
- PROTEIN_SECRETION-0.220
- FATTY_ACID_METABOLISM-0.140
- HEME_METABOLISM-0.120
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.120
- CHOLESTEROL_HOMEOSTASIS-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR615467 | GTEX | — | 0.852 |
| 2 | 8914dcad-b703-4099-a5dd-edb9cedc104c | — | — | 0.830 |
| 3 | 4ff81b7f-2dbc-453f-a68b-fe40315b2ef7 | — | — | 0.829 |
| 4 | s0122319 | — | — | 0.820 |
| 5 | TCGA-OR-A5J8-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.820 |
| 6 | MDT-AP-1239 | Med | Medulloblastoma | 0.820 |
| 7 | MDT-AP-2990 | Med | Medulloblastoma | 0.820 |
| 8 | MNG523 | — | — | 0.819 |
| 9 | TCGA-MP-A4TI-01A-21R-A24X-07 | — | cohortA1 | 0.816 |
| 10 | s_150203_5b | EPN | Posterior Fossa EPN | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |